the problem.
Allergy Testing Hasn't Advanced in 150 Years
Past ~ Oral Food Challenge
Future ~ BAT Assay
the solution.
4 Simple Steps
~ Amerimmune is leading the charge away from antiquated allergy testing methods with a patented Virtual Food Challenge.
~ Represents a new "gold standard."
~ One sample of the patient’s blood is all it takes.
advancing patient care.
~ As one of the most highly respected immunology labs in the US, Amerimmune receives blood from private doctors offices, universities, and individual patients nationwide.
~ Historically, blood-based allergy tests are static; doesn't measure how the body reacts to allergen.
~ Amerimmune's expertise lies in specialized functional assays that measure the how the bodies immune system will respond to the allergen.
~ Today, Amerimmune and its partner clinics, are the ONLY practices in the US that offers food allergy basophil activation tests as a validated CLIA/CAP assay (48 hour virtual allergy testing).
~ Amerimmune has performed over 1000 clinical grade BAT tests on samples from across the United States.
Amerimmune’s Discovery
The prevailing myth has been that allergy test blood samples lost their efficacy after 4 hours.
The results of Amerimmune's peanut-focused Basophil Activation Test (BAT), published in the peer-reviewed journal Cytometry B, revealed that with the right system samples remained usable for 48 hours. A viable "virtual" allergy test was finally possible.
Rate of up-regulation in a combination of surface and intra-cellular proteins allow a better performance of the assay.
Refining BAT
~ Amerimmune's team has gone beyond addressing the "time" factor of the Basophil Activation Allergy testing.
~ Focus on addressed the long-known shortcomings of the BAT test thereby enhancing accuracy.
~ Amerimmune filed provisional patent applications related to these discoveries.
~ Will continue to optimize the tests as a part of the FDA Clearance application.
Make it stand out.
BAT: the first virtual peanut challenge test
~ Amerimmune R&D is set to become the "gold standard" of virtual peanut challenge testing.
~ No need to consume potentially lethal foods (like peanuts) in a clinical setting.
~ The $5 billion+ allergy testing market will finally have a viable kit-based solution that both hospitals and clinicians can implement immediately.